Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive HIV-Infected Individuals
Author(s) -
G. Antonucci,
Enrico Girardi,
Alessandro CozziLepri,
Maria Rosaria Capobianchi,
Andrea De Luca,
Massimo Puoti,
E. Petrelli,
G Carnevale,
Giuliano Rizzardini,
Paolo Grossi,
P. Vigany,
Maria Cristina Moioli,
Fabrizio Carletti,
Mariacarmela Solmone,
Giuseppe Ippolito,
Antonella d’Arminio Monforte
Publication year - 2005
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/430445
Subject(s) - viremia , hepatitis c virus , medicine , virology , immunology , hepatitis c , genotype , hepacivirus , viral disease , immune system , viral load , lentivirus , antibody , virus , biology , biochemistry , gene
The roles of hepatitis C virus (HCV) viremia and HCV genotype in the immune response to highly active antiretroviral therapy (HAART) are poorly understood. Our aim was to assess the CD4+ cell count recovery after HAART in human immunodeficiency virus (HIV)-infected patients with HCV viremia and HIV-infected patients who tested negative for HCV antibody (HCV-Ab). We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom